Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

39P - Analysis of the immune response patterns in localized prostate cancer

Date

12 Dec 2024

Session

Poster Display session

Presenters

Sara Merler

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-16. 10.1016/iotech/iotech100742

Authors

S. Merler1, B. Calì2, S. Zumerle3, D. Braga2, V. Moscarda4, D. Minardi5, F. Carletti5, G. Randazzo5, G. Reitano5, M. Minini6, F. Galuppini7, M. Fassan5, A. Morlacco5, F. Dal Moro4, A. Zivi8, M. Milella8, S. Gillessen9, A. Alimonti9

Author affiliations

  • 1 Oncology Institute of Southern Switzerland, Bellinzona/CH
  • 2 IOR - Institute of Oncology Research, Bellinzona/CH
  • 3 IOV - Istituto Oncologico Veneto IRCCS, Padova/IT
  • 4 Azienda Ospedaliera Universitaria Integrata Verona, Verona/IT
  • 5 Azienda Universitaria Ospedaliera di Padova, Padova/IT
  • 6 University of Padova, Padova/IT
  • 7 University of Padua, Padova/IT
  • 8 University of Verona and University and Hospital Trust (AOUI) of Verona, Verona/IT
  • 9 EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona/CH

Resources

This content is available to ESMO members and event participants.

Abstract 39P

Background

Prostate cancer (PCa) is one of the leading malignant diseases in men worldwide. The presence of myeloid-derived suppressor cells (PMN-MDSCs) is a critical contributor to a pro-tumorigenic microenvironment in advanced disease, where the neutrophil-lymphocyte ratio (NLR) is prognostic. However, their involvement in the early stages of PCa is still unclear.

Methods

Patients affected by localized prostate cancer and undergoing radical prostatectomy at the Urology Department of the University Hospital of Padua were enrolled in the study after signing informed consent. Blood and tumor samples from 79 patients were collected and immunostained for flow cytometry analysis. Disease risk groups were assigned according to EAU guidelines. Correlation between experimental data and clinical and anatomopathological features was done by logistic regression and Sperman’s correlation.

Results

No association between neutrophil counts and NLR with oncological outcome was found in a population of 79 patients with localized prostate cancer. However, a subset of circulating immature myeloid cells was found to be associated with higher disease risk groups (OR = 1.19 CI.95 (1.02, 1.38), p-value = 0.027). Of note, primary tumor lesions did not reveal a significant enrichment of the immune infiltrate and any association with clinical scores. Further analyses on defining a new potential circulating biomarker showed encouraging results. Gene expression analyses are ongoing.

Conclusions

Localized PCa is not associated with a higher circulating number of neutrophils and higher NLR compared with healthy subjects. However, further analyses of specific myeloid cell subsets are needed.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.